Pfizer Gets EU OK for INLYTA, a Cancer Pill, as Second Treatment (PFE, INFA)
** Pfizer Inc. (NYSE:PFE) reported that the European Commission (EC) has granted marketing authorization for INLYTA(R) (axitinib) for the treatment of adult patients with advanced renal cell carcinoma (RCC), a type of kidney cancer, after failure of prior treatment with suni
Online PR News – 04-September-2012 – Las Vegas, NV – PFE, Pfizer Inc.
PFE reported that the European Commission (EC) has granted marketing authorization for INLYTA(R) (axitinib) for the treatment of adult patients with advanced renal cell carcinoma (RCC), a type of kidney cancer, after failure of prior treatment with sunitinib or a cytokine. Renal cell carcinoma is the sixth leading cause of cancer-related death. At diagnosis, approximately a third of kidney cancer patients will have advanced disease, where the cancer has spread to multiple parts of the body and prognosis is poor. The incidence of RCC in Europe is 102,000 people per year. Between 40 and 65 percent of patients worldwide who progress following first-line therapy go on to receive a second-line treatment. Pfizer Oncology is committed to the discovery, investigation and development of innovative treatment options to improve the outlook for cancer patients worldwide. More about PFE at www.pfizer.com
INFA, Informatica Corporation
INFA was upgraded from Neutral to Outperform by Brokerage Firm Robert W. Baird INFA is the world's number one independent provider of data integration software. More about INFA at www.informatica.com
The Internet is the newest of the traditional media. A main advantage of Internet advertising is its affordability as an advertising medium. Crown Equity Holdings Inc., (CRWE) offers advertising branding and marketing services as a worldwide online multi-media publisher with its digital network of websites and focuses on the distribution of information for the purpose of bringing together a targeted audience and the advertisers that want to reach them. CRWEs advertising services cover and connect a range of marketing specialties, as well as provide search engine optimization for clients interested in online media awareness. CRWEs division CRWE AD-Services (www.crwe-adservices.com), is a full service multimedia advertising company specializing in internet marketing. It provides modern and unique advertising campaigns, dedicated to offering the most cost effective advertising solutions. More about CRWE at www.crownequityholdings.com.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY! Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. BestOtc.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer ( http://bestotc.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold BestOTC.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE) advertises for a particular client, Crown Equity Holdings Inc. (CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE), if paid in stock, can and may sell those securities during the advertising period.
Copyright 2015 Online PR Media | 507 Casazza Dr Ste A, Reno, NV 89502